588 related articles for article (PubMed ID: 26085683)
41. Target cell CD47 regulates macrophage activation and erythrophagocytosis.
Olsson M; Nilsson A; Oldenborg PA
Transfus Clin Biol; 2006; 13(1-2):39-43. PubMed ID: 16564725
[TBL] [Abstract][Full Text] [Related]
42. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology.
Burgess TL; Amason JD; Rubin JS; Duveau DY; Lamy L; Roberts DD; Farrell CL; Inglese J; Thomas CJ; Miller TW
PLoS One; 2020; 15(4):e0226661. PubMed ID: 32240171
[TBL] [Abstract][Full Text] [Related]
43. Blockade of CD47 or SIRPα: a new cancer immunotherapy.
Murata Y; Saito Y; Kotani T; Matozaki T
Expert Opin Ther Targets; 2020 Oct; 24(10):945-951. PubMed ID: 32799682
[TBL] [Abstract][Full Text] [Related]
44. SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy.
Veillette A; Chen J
Trends Immunol; 2018 Mar; 39(3):173-184. PubMed ID: 29336991
[TBL] [Abstract][Full Text] [Related]
45. SIRPα controls the activity of the phagocyte NADPH oxidase by restricting the expression of gp91(phox).
van Beek EM; Zarate JA; van Bruggen R; Schornagel K; Tool AT; Matozaki T; Kraal G; Roos D; van den Berg TK
Cell Rep; 2012 Oct; 2(4):748-55. PubMed ID: 23022485
[TBL] [Abstract][Full Text] [Related]
46. Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.
Theocharides AP; Jin L; Cheng PY; Prasolava TK; Malko AV; Ho JM; Poeppl AG; van Rooijen N; Minden MD; Danska JS; Dick JE; Wang JC
J Exp Med; 2012 Sep; 209(10):1883-99. PubMed ID: 22945919
[TBL] [Abstract][Full Text] [Related]
47. A single-valent long-acting human CD47 antagonist enhances antibody directed phagocytic activities.
Wu F; Qiu Y; Xu Y
Cancer Immunol Immunother; 2020 Dec; 69(12):2561-2569. PubMed ID: 32583154
[TBL] [Abstract][Full Text] [Related]
48. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding.
Petrova PS; Viller NN; Wong M; Pang X; Lin GH; Dodge K; Chai V; Chen H; Lee V; House V; Vigo NT; Jin D; Mutukura T; Charbonneau M; Truong T; Viau S; Johnson LD; Linderoth E; Sievers EL; Maleki Vareki S; Figueredo R; Pampillo M; Koropatnick J; Trudel S; Mbong N; Jin L; Wang JC; Uger RA
Clin Cancer Res; 2017 Feb; 23(4):1068-1079. PubMed ID: 27856600
[No Abstract] [Full Text] [Related]
49. Versatile activatable vSIRPα-probe for cancer-targeted imaging and macrophage-mediated phagocytosis of cancer cells.
Ko YJ; Lee JW; Kim H; Cho E; Yang Y; Kim IS; Kim SH; Kwon IC
J Control Release; 2020 Jul; 323():376-386. PubMed ID: 32335154
[TBL] [Abstract][Full Text] [Related]
50. Dose-dependent inhibitory effect of CD47 in macrophage uptake of IgG-opsonized murine erythrocytes.
Olsson M; Nilsson A; Oldenborg PA
Biochem Biophys Res Commun; 2007 Jan; 352(1):193-7. PubMed ID: 17112468
[TBL] [Abstract][Full Text] [Related]
51. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
[TBL] [Abstract][Full Text] [Related]
52. Selection and Characterization of FD164, a High-Affinity Signal Regulatory Protein
Wang Z; Hu N; Li X; Wang H; Ren C; Qiao C; Chen G; Wang J; Zhou L; Wu J; Zhang D; Feng J; Shen B; Peng H; Luo L
Mol Pharmacol; 2021 Sep; 100(3):193-202. PubMed ID: 34315811
[TBL] [Abstract][Full Text] [Related]
53. SIRPA-Inhibited, Marrow-Derived Macrophages Engorge, Accumulate, and Differentiate in Antibody-Targeted Regression of Solid Tumors.
Alvey CM; Spinler KR; Irianto J; Pfeifer CR; Hayes B; Xia Y; Cho S; Dingal PCPD; Hsu J; Smith L; Tewari M; Discher DE
Curr Biol; 2017 Jul; 27(14):2065-2077.e6. PubMed ID: 28669759
[TBL] [Abstract][Full Text] [Related]
54. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
55. CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.
Gao L; Chen K; Gao Q; Wang X; Sun J; Yang YG
Oncotarget; 2017 Apr; 8(14):22406-22413. PubMed ID: 27283989
[TBL] [Abstract][Full Text] [Related]
56. Deletion of CD47 from Schwann cells and macrophages hastens myelin disruption/dismantling and scavenging in Schwann cells and augments myelin debris phagocytosis in macrophages.
Gitik M; Elberg G; Reichert F; Tal M; Rotshenker S
J Neuroinflammation; 2023 Oct; 20(1):243. PubMed ID: 37872624
[TBL] [Abstract][Full Text] [Related]
57. An antitumor peptide RS17-targeted CD47, design, synthesis, and antitumor activity.
Wang X; Wang Y; Hu J; Xu H
Cancer Med; 2021 Mar; 10(6):2125-2136. PubMed ID: 33629544
[TBL] [Abstract][Full Text] [Related]
58. Osteoclast formation is strongly reduced both in vivo and in vitro in the absence of CD47/SIRPalpha-interaction.
Lundberg P; Koskinen C; Baldock PA; Löthgren H; Stenberg A; Lerner UH; Oldenborg PA
Biochem Biophys Res Commun; 2007 Jan; 352(2):444-8. PubMed ID: 17126807
[TBL] [Abstract][Full Text] [Related]
59. Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
Wang Y; Zhao C; Liu Y; Wang C; Jiang H; Hu Y; Wu J
Mol Pharm; 2022 May; 19(5):1273-1293. PubMed ID: 35436123
[TBL] [Abstract][Full Text] [Related]
60. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
